GenEdit, a venture from the spring 2016 CITRIS Foundry cohort, has received $26 million from Eli Lilly and Co. and nearly a dozen other investors to support its efforts to develop safer gene therapy delivery methods. Its NanoGalaxy platform uses nonviral, nonlipid polymer nanoparticles to selectively target tissue while bypassing patients’ immune responses.
Read more about GenEdit’s latest milestone in Chemical & Engineering News, Endpoints News, and Fierce Biotech.
Learn more about GenEdit’s genesis from CEO Kunwoo Lee, in a video from CITRIS Productions.